Why ask your CRO to use Pinnacle 21 Enterprise?

Sponsors rely on CROs to manage data quality and regulatory readiness. But gaps in validation processes can introduce rework, delays, and compliance risks. While many CROs default to Pinnacle 21 Community, this approach often falls short in large scale and late phase studies. Requesting Pinnacle 21 Enterprise ensures better oversight, collaboration, and submission readiness from study setup.

In this blog we explore how your CRO’s choice of validation platform can directly impact your study’s success. Specifically, we consider:

• Where Pinnacle 21 Community creates risks in CRO-led workflows
• When and why sponsors should require CROs to adopt Enterprise
  • Where Enterprise adds significant value
  • How Enterprise makes a difference

When Pinnacle 21 Community stops being enough

Pinnacle 21 Community is an established solution for basic validation requirements, particularly for small clinical studies. But as studies move from early phase to later stage development, validation complexity rapidly increases. This is particularly seen in the increased number of datasets and cross-domain dependencies.

What works for Phase 1 studies quickly becomes difficult to manage across Phase 2 and beyond, where validation becomes a continuous, multi-stakeholder process – rather than a one-time activity.

When CROs rely solely on Community, sponsors risk:

Unreliable validations

Without a centralized validation standard, variability in how and when CROs apply validation rules can leave sponsors exposed to discrepancies between submitted data and regulatory expectations. This risk is compounded since Community is not guaranteed to be aligned with the latest validation engine updates. As a result, teams may validate against different rule versions, creating further inconsistencies.

Delayed issue resolution

Without centralized, real-time issue management, CROs are left to manage hundreds or thousands of findings in spreadsheets across multiple reruns. This makes it extremely difficult to track, assign, and resolve issues promptly. Such inefficiencies often lead to prolonged data discrepancies, which impacts timelines.

Delays in submission readiness

Manual creation of submission deliverables risks errors in define.xml packages. This increases rework and impacts sponsor timelines. Manual generation of Study Data Reviewer’s Guides further compounds the risk of inconsistencies and delays. The absence of insight into submission readiness – and the required steps to achieve this – also jeopardizes successful sponsor submissions.

Lack of oversight & control

Sponsors rely on static validation outputs, which means no visibility into what was run, when, and by who. The absence of a collaborative platform also limits visibility into resolution progress and submission readiness. With no centralized audit trail of validation and issue lifecycles, sponsors lack the visibility needed to effectively manage and control CRO partnerships.

Why Community workflows break down at scale

As study size and complexity increase, validation expands from a single task into a fully managed process. Community-based workflows stop being fit-for-purpose due to structural limitations.

These gaps mean that CROs using Community are not best placed to deliver timely, compliant submissions.

Where Community workflows create risk

How Pinnacle 21 Enterprise closes the gaps left by Community

Pinnacle 21 Enterprise is purpose-built to mitigate sponsor risk by providing a collaborative environment that strengthens validation assurance. When sponsors ask CROs to use Enterprise, they gain:

Centralized validation and issue management

Enterprise provides a central platform where validation and issue activities are automatically captured, tracked, and managed across sponsors and CROs. This creates a single source of truth for real-time collaboration across stakeholders. And with both ‘fix tips’ and pre-written explanations, sponsors benefit from swifter issue resolution.

• Standardized validation processes across studies
• Full history across the validation lifecycle
• Built-in issue tracking and resolution with full audit trails
• Reusable ‘fix tips’ with pre-written explanations

Read how Macrogenics Biopharma improved validation outcomes with Pinnacle 21 Enterprise: https://www.certara.com/case-study/validation-in-clinical-data-management-macrogenics-optimizes-validation-and-issue-management-with-pinnacle-21-enterprise/

Increased regulatory compliance & submission-readiness

Pinnacle 21 Enterprise is maintained in line with the very latest version of the validation engine. This gives sponsors confidence that validation is consistently aligned with current regulatory expectations, reducing the risk of discrepancies and rework delays.

‘Data fitness’ scores in Enterprise provide a real-time, ongoing measure of how close a study is to submission readiness. This gives sponsors the visibility needed to track progress and intervene earlier where needed. Data package specific guidance leads CROs towards improved compliance scores and regulatory readiness.

• Prompt alignment with the latest version of the validation engine
• Alignment with the latest validation rules across global agencies (including FDA and PMDA)
• Consistent application of CDISC standards and Controlled Terminology
• Quantitative measure of submission readiness with guided resolution steps

Improved data consistency

Pinnacle 21 Enterprise helps ensure submission packages are accurate, consistent, and aligned with regulatory expectations from the outset – while maintaining that consistency across the full study lifecycle.

• Automated generation of regulatory-aligned Reviewer’s Guides
• Up to 80% auto-population of compliant define.xml packages
• Consistent application of standards, rules, and metadata across all studies and partners
• Continuous issue tracking across validation runs and reruns
• Standardized issue explanations for consistent Reviewer’s Guides

Greater CRO validation oversight

Centralized collaboration and portfolio-level visibility in Enterprise provide a single source of truth, allowing sponsors to proactively monitor progress, enforce accountability, and address issues before they impact timelines or submissions.

• Shared access to validation results and issue status
• Portfolio-level dashboards across studies:
  • Metrics for data quality, progress, and submission readiness
• Early identification of recurring issues and risk trends
• Full audit trail for complete traceability and inspection readiness

How Pinnacle 21 Enterprise compares to Community

This value becomes even more apparent when sponsors manage multiple CRO partners.

On average, organizations using Enterprise report up to 80% time savings across validation, issue management, and submission deliverable generation. For sponsors, this translates into reduced risk and greater confidence that submission milestones will be met.

Summary and next steps

As clinical trials become more complex, relying on Community alone introduces unnecessary risk. Asking your CRO to use Pinnacle 21 Enterprise is a strategic decision to improve data quality, accelerate timelines, and reduce regulatory risk. By enabling transparency, collaboration, and scalability, Enterprise helps ensure your study is submission-ready from day one.